UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Discover effective ways to increase your investment portfolio performance. Enhance your returns and achieve your financial goals.
23,604 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Goldman Sachs and JPMorgan cut targets on Kohl’s as consumer demand cools, signaling a tougher 2026. The moves come a...
Oil volatility could create a rare buy-on-dip window for memory names. Jim Cramer says Western Digital and Micron may...
Investors pulled back from spot XRP ETFs this week, registering zero net inflows across seven trading sessions. XRP p...
Strategy disclosed a large BTC buy funded by STRC, boosting its holdings and shifting crypto funding toward yield-dri...
Crypto markets tank $100B in a single session as the Federal Reserve signals a hawkish stance and likely fewer rate c...
U.S. prosecutors allege a scheme to move Nvidia GPUs and servers to China, with Supermicro’s co-founders at the cente...
CEOs are shifting from a single forecast to multi-scenario, wartime-style planning to weather shocks. CFOs play a piv...
As mortgage markets tighten and churn rises, lenders are turning to mentorship to convert recruits into steady, produ...
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
Lawmakers delay a major stablecoin bill, triggering renewed frustration across crypto traders as markets react to pol...
Hut 8's stock surged on news of a landmark AI data center deal valued at $9.8 billion, positioning the crypto miner t...